Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models

Show full item record



Permalink

http://hdl.handle.net/10138/157013

Citation

Penttinen , K , Swan , H , Vanninen , S , Paavola , J , Lahtinen , A M , Kontula , K & Aalto-Setala , K 2015 , ' Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models ' , PLoS One , vol. 10 , no. 5 , 0125366 . https://doi.org/10.1371/journal.pone.0125366

Title: Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models
Author: Penttinen, Kirsi; Swan, Heikki; Vanninen, Sari; Paavola, Jere; Lahtinen, Annukka M.; Kontula, Kimmo; Aalto-Setala, Katriina
Contributor: University of Helsinki, Clinicum
University of Helsinki, Minerva Fdn
University of Helsinki, Clinicum
University of Helsinki, Clinicum
Date: 2015-05-08
Language: eng
Number of pages: 17
Belongs to series: PLoS One
ISSN: 1932-6203
URI: http://hdl.handle.net/10138/157013
Abstract: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a highly malignant inherited arrhythmogenic disorder. Type 1 CPVT (CPVT1) is caused by cardiac ryanodine receptor (RyR2) gene mutations resulting in abnormal calcium release from sarcoplasmic reticulum. Dantrolene, an inhibitor of sarcoplasmic Ca2+ release, has been shown to rescue this abnormal Ca2+ release in vitro. We assessed the antiarrhythmic efficacy of dantrolene in six patients carrying various RyR2 mutations causing CPVT. The patients underwent exercise stress test before and after dantrolene infusion. Dantrolene reduced the number of premature ventricular complexes (PVCs) on average by 74% (range 33-97) in four patients with N-terminal or central mutations in the cytosolic region of the RyR2 protein, while dantrolene had no effect in two patients with mutations in or near the transmembrane domain. Induced pluripotent stem cells (iPSCs) were generated from all the patients and differentiated into spontaneously beating cardiomyocytes (CMs). The antiarrhythmic effect of dantrolene was studied in CMs after adrenaline stimulation by Ca2+ imaging. In iPSC derived CMs with RyR2 mutations in the N-terminal or central region, dantrolene suppressed the Ca2+ cycling abnormalities in 80% (range 65-97) of cells while with mutations in or near the transmembrane domain only in 23 or 32% of cells. In conclusion, we demonstrate that dantrolene given intravenously shows antiarrhythmic effects in a portion of CPVT1 patients and that iPSC derived CM models replicate these individual drug responses. These findings illustrate the potential of iPSC models to individualize drug therapy of inherited diseases.
Subject: CARDIAC RYANODINE RECEPTOR
PLURIPOTENT STEM-CELLS
MALIGNANT HYPERTHERMIA
THERAPEUTIC AGENT
FOLLOW-UP
MUTATIONS
CARDIOMYOCYTES
DYSFUNCTION
CALMODULIN
RELEASE
3121 Internal medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Antiarrhythmic_ ... nses_Using_iPSC_Models.pdf 8.484Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record